

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of August 2025**

Commission File Number: **001-35165**

**BRAINSWAY LTD.**

(Translation of registrant's name into English)

**16 Hartum Street RAD Tower, 14th Floor**

**Har HaHotzvim**

**Jerusalem, 9777516, Israel**

**(+972-2) 582-4030**

(Address and telephone number of Registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ **X**    Form 40-F ☐    ]

This Form 6-K is incorporated by reference into the Company's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 22, 2019 (Registration No. 333-230979) and the Company's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 22, 2024 (Registration No. 333-280934) and on April 22, 2025 (Registration No. 333-286672).

---

## EXHIBIT INDEX

Exhibit	Title
<a href="#">99.1</a>	<a href="#">Corporate Presentation</a>

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BRAINSWAY LTD.**  
(Registrant)

Date: August 13, 2025


/s/ Hadar Levy  
Hadar Levy  
Chief Executive Officer



# A New Era in Brain Disorder Treatment

## Corporate Presentation

Nasdaq/TASE: BWAY  
August 2025



## Safe Harbor and Non-GAAP/IFRS Financial Measures

This presentation does not constitute an offer or invitation to sell or issue, or any solicitation of an offer to subscribe for or acquire any of the Company's securities or to participate in any investment in the Company. This presentation shall not constitute advertising or misconstrued as being commercial and/or promotional in nature. No representation or warranty is made to the accuracy or completeness of this presentation. You must make your own investigation and assessment of the matters contained herein. In particular, no representation or warranty is given, and the Company has no responsibility, as to the achievement or reasonableness of any forecasts, estimates, or statements as to prospects contained or referred to in this presentation.

This presentation contains information that includes or is based on forward-looking statements within the meaning of the federal securities law. These statements are not guarantees of future performance, are based on current expectations of future events and are subject to various risks and uncertainties that could cause our actual activities, timing or results to differ materially from those expressed or implied in such statements. Such factors include, but are not limited to: continued business impact from the COVID-19 global pandemic; weakening of economic conditions that could adversely affect the level of demand for our products; pricing pressures generally; difficulties or delays in manufacturing; legislative and regulatory actions; changes in reimbursement level from third-party payors; product liability claims; the impact of federal legislation to reform the United States healthcare system; changes in financial markets; changes in the competitive environment; failure to gain sufficient market adoption of our products; regulatory actions or delays; and our ability to realize anticipated operational and manufacturing efficiencies. Additional information concerning these and other factors, including the Risk Factors set forth therein, is contained in our filings with the U.S. Securities and Exchange Commission. The forward-looking statements in this presentation are made based upon our current expectations. If one or more of these factors materialize, or if any underlying assumptions prove incorrect, our actual results, performance or achievements may vary materially from any future results, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements as a prediction of actual results. In addition, the presentation contains certain data and information that we obtained from various government and private publications. Statistical data in these publications also include projections based on a number of assumptions. If any one or more of the assumptions underlying the market data are later found to be incorrect, actual results may differ from the projections based on these assumptions. You should not place undue reliance on these forward-looking statements. All forward-looking statements included in this presentation are made only as of the date of this presentation. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.

Certain non-GAAP/IFRS financial measures are included in this presentation, which are designed to complement the financial information presented in accordance with IFRS, because management believes such measures are useful to investors. For example, we believe that Adjusted EBITDA, a non-IFRS measure, is useful in evaluating our operating performance, because (a) it is widely used by investors and securities analysts to measure a company's operating performance without regard one-time items (such as restructuring and litigation expenses), that can vary substantially from company to company; and (b) management uses Adjusted EBITDA in conjunction with IFRS financial measures for planning purposes, including the preparation of our annual operating budget, as a measure of operating performance. These non-GAAP/IFRS financial measures should be considered only as supplemental to, and not superior to, financial measures provided in accordance with IFRS. Other companies may calculate similarly titled non-GAAP/IFRS financial measures differently than the Company.

# BrainsWay (BWAY) at a Glance



## Advancing Neuroscience to Improve Health and Transform Lives

- ✓ BrainsWay is a fast-growing global leader in advanced noninvasive neurostimulation treatments for mental health disorders
- ✓ First and only TMS company to obtain 4 FDA-cleared indications (MDD, OCD, Anxious Depression, Smoking Addiction)
- ✓ Transition to a recurring revenue model through rentals and pay-per-use agreements, providing predictable and sustainable cash flow
- ✓ Backlog and remaining performance obligations \$62 million
- ✓ Broad reimbursement among commercial and governmental payors
- ✓ Global presence in key markets including the U.S., Canada, Asia, India, and Europe
- ✓ Proven, differentiated noninvasive neurostimulation platform technology
- ✓ Strong balance sheet with ~\$78 million in cash and no debt
- ✓ NASDAQ: BWAY; MC: \$230M

Corporate Presentation August 2025



# Strategic Partnership with Valor Equity Partners




Valor's Support Strengthens Our Position as a Leader in the TMS Industry



- Closed \$20M equity financing with Valor, a top-tier U.S. tech investor
- Expertise in High-Growth Companies
- Invest in innovation
- Scaling growth
- Access to best practices

## SERVING DISRUPTIVE COMPANIES FOR 25+ YEARS



# BrainsWay by the Numbers



## Strong Fundamentals for Growth

**~\$52m**

**Revenue**  
2025 guidance

**75%**

**Gross Margin**  
2025 guidance

**\$78m**

**Cash Balance**  
as of Q2 2025

**1,522**

**Total Installed Base**  
as of Q2 2025

**\$7M**

**Adjusted EBITDA\***  
2025 guidance

**\$62M**

**Signed Backlog**  
Q2 2025

**880**

**OCD Systems**  
as of Q2 2025

**6.3M**

**Deep TMS Treatments**  
220K+ Patients

**35+**



**Completed Clinical Trials**  
360+ Deep TMS™ publications

\* Adjusted EBITDA is a Non-IFRS Measure. See slide 28 for operating income results, the closest IFRS measure, and the reconciliation table in the Company's Earnings release

# Q2 2025 Executive Summary



- Revenue: \$12.6M, up 26% YoY
- Operating income totaled \$0.6 million and Adjusted EBITDA rose to \$1.5 million
- Net Profit: \$2M up 240% YoY
- Remaining performance obligations increased by 25 % YOY to \$62 million
- Eight consecutive quarters of positive free cash flow
- Raised full-year 2025 Revenue and EBITDA guidance
- 70% of recent customer engagements are structured as multi-year lease agreements
- Cash Position: \$78.3M in cash and short-term deposits, no debt
- 88 systems shipped in Q2 2025, up 35% YoY
- Installed base: Reached +1,522 systems globally
- Stella MSO: Completed equity financing with a top-performing clinic network
- Several opportunities currently being explored
- FDA Submission: Accelerated MDD and adolescence submitted for review
- PTSD Expansion: Collaboration with Israel's Ministry of Defense for soldiers



# How Do We Partner?



## Flexible Business Model Leads to Better Adoption

MDD / OCD

### Lease: ~60%


Creates long-term stable revenue stream for BrainsWay  
Unlimited use with a fixed annual fee; 4-5 year contracts

### Direct purchase: ~30%

One time purchase; maintenance fee for the following years  
Mainly through distribution channels

### Growth Incentive model: ~10%

Reduces upfront capital commitment for physicians  
Pay-per-use fee; 4-5 year contracts



# Revenue & Adjusted EBITDA



## Strong RPO Drives Clear Visibility Into Future Growth


- **\$20 million in binding contracts (RPO)**
- This translates into an **annual revenue run-rate of ~\$20 million**, providing clear

- **Recurring revenue grew ~45% year-over-year**, outpacing overall company growth

- Approximately **70% of new contracts are multi-year rental agreements**, compared to less than 40% two years ago

- **Customer retention rate** (by number of clinics) stands at **~93%**

- Some clinics are renewing and purchasing an additional system – indicating **potential NRR above 100%**



\* Adjusted EBITDA is a Non-IFRS Measure. See slide 28 for operating income results, the closest IFRS measure, and the reconciliation table in the Company's Earnings release

# Strategic Equity Investments in Mental Health Providers



**New Strategy to  
Accelerate  
Company Growth**

**200+ Mental Health  
Clinics Identified**

**Strategic Initiative  
Led by Valor Fund**

**Each Deal Can  
Potentially Add 10 -  
15 Clinics Anually**

**Highly Profitable  
Deals  
No Added OPEX**

# Strategic Partnership with Stella



- ✓ 5\$M minority investment in Stella - a leading U.S.-based interventional psychiatry platform
- ✓ Structured as a preferred, compounding equity stake
- ✓ Joint business planning and strategic growth support

## ✓ About Stella


- ✓ 20+ clinics across the U.S. and Israel
- ✓ 30,000+ patients treated to date
- ✓ Known for clinical excellence, operational strength, and innovative care delivery



Corporate Presentation August 2025

# Stella

## Mental Health



# 2025 – Pivotal Year for BrainsWay



## Superior Science, Evidence, and Support Drive Growth

### Technology Innovation

- Launch Insights Cloud
- Introduce TMS 360
- Development of next-gen Deep TMS system
- AI-driven personalization tool to optimize treatment protocols
- Home use device

Corporate Presentation August 2025

### Clinical Research\*

- Adolescent MDD
- Accelerated Deep TMS
- Alcohol trial launch
- PTSD data collection for label expansion
- Launch of clinical trials combining Deep TMS with psychedelic therapies

\*Not FDA-cleared

### Sales & Support Initiatives

- Strategic partnerships with mental health networks & addiction centers
- OCD expansion
- Practice Development Program

11

## Expanding Market Opportunities with Potential New Indications



Indications	Pre-Phase Clinical Trials	Randomized Controlled Trials	FDA Submission	Commercial Phase	U.S. Patient Population
Major Depressive Disorder (MDD)+ Anxious Depression					21M
Obsessive-compulsive Disorder (OCD)					3M
Smoking Addiction					34M
Alcohol Use Disorder <sup>1</sup> (AUD)					29M
Alzheimer <sup>1</sup> (aged 65+)					7M
Post-Stroke <sup>1</sup>					1M

<sup>1</sup>) Note: Other than MDD, OCD, and Smoking Addiction, the above indications are currently investigational, not available in the U.S., and not cleared by the FDA

Corporate Presentation August 2025

# BrainsWay in Use



Academic Institutions and Private Clinics Worldwide Use BrainsWay Technology

**6.3M+** Deep TMS sessions

**220K+** Patients successfully treated

across **47** US States

and **6** Continents

Corporate Presentation August 2025



**Leveraged in Clinical Trials  
By Major Academic  
Centers of Excellence**



**JOHNS HOPKINS**  
MEDICINE



**Duke University**  
Medical Center



**McLean**  
HARVARD MEDICAL SCHOOL AFFILIATE



**COLUMBIA UNIVERSITY**  
MEDICAL CENTER



**Harbor-UCLA**  
MEDICAL CENTER



**MUSC Health**  
MEDICAL UNIVERSITY of SOUTH CAROLINA



**UC DAVIS**  
Center for Mind and Brain




**UT SOUTHWESTERN**  
MEDICAL CENTER

# Continuum of Care for Depression and OCD



## Massive Underserved Markets



# Transcranial Magnetic Stimulation (TMS)




**Established Technology with Demonstrated Safety and Efficacy**

## Comprehensively Studied

Over 25,000 published papers on TMS<sup>8</sup>

### How Does it Work?

1. An electromagnetic coil is placed over the scalp
2. A fast current is produced in the coil
3. Electromagnetic field is induced in the brain
4. Rapidly changing electric field in the brain, leading to axonal depolarization and action potentials
5. 2.5 times deeper than Standard TMS
6. Deeper and broader stimulation leads to activation of more neurons.




Corporate Presentation August 2025

15

# Evolution of TMS



TMS has Been Used for > 35 Years with BrainsWay Pioneering Key Innovations



# BrainsWay Delivers Proven Records



Deep TMS Therapy Has Significant Appeal to Providers and Patients



Noninvasive  
Technology



No Anesthesia  
Required



Well-Tolerated  
by Patients



~3 to 20 Minute  
Sessions



Easy to  
Administer




Strong  
Reimbursement

Corporate Presentation August 2025

# BrainsWay Deep TMS™ Advantages over Traditional TMS<sup>1</sup>



BrainsWay's Clinical Advantages are Clear and Compelling



Deep TMS activates more neurons and reduces likelihood of targeting errors

# Strong Economic and Clinical Incentive for Adopters



## Robust Reimbursement Coverage Drives Compelling Clinician ROI



# Depression Clinical Efficacy



## Substantial Body of Clinical Evidence Demonstrating Safety and Efficacy

### Real Clinical Practice Settings<sup>12</sup>

After 30 Sessions

81.6%

Response

65.3%

Remission

~2 in 3 Patients Achieved Remission with Deep TMS

- 1,351 MDD patients who received at least 20 Deep TMS sessions
- No systemic side effects

Durability in TMS is 1+ Year in ~50% of Responders<sup>13</sup>

- A published abstract of 100 patients from a single BrainsWay site showed average durability of 860 days<sup>14</sup>

\*Response and remission assessed from patient and/or physician rating scales

20



# OCD Clinical Efficacy



Only TMS System with Clinically Demonstrated Safety and Efficacy Outcomes

## Real Clinical Practice Settings<sup>15</sup>

After 29 Sessions

57.9%

Response

### >1 in 2 Patients Achieved Response

- 219 patients from 22 worldwide centers
- Sustained response achieved in ~20 sessions
- No systemic side effects

### 87% Demonstrated Durability of 1+ Year<sup>16</sup>

- 60 patients from pivotal and post-marketing studies
- "Durability" defined as the elapsed time from the end of the Deep TMS treatment course until there was a change in ongoing treatment



# Smoking Addiction



Smokers Spend Nearly \$2B/year on Quitting and ~85% are Unsuccessful

**28.3m**

U.S. Adult Smokers<sup>17</sup>  
68% are Motivated to Quit

**7.6m**

Made Serious Quit Attempt  
using prescription medication or nicotine  
replacement therapy (NRT)

**4.7m**

Smokers who were NOT successful quitting  
with cessation medication or psychotherapy<sup>18</sup>

**Deep TMS™**

Transcranial Magnetic Stimulation

Double-Blind, Placebo-Controlled RCT<sup>19</sup>

Nearly 1 in 3 Quit for 4 Weeks

2 of 3 Completers at Week 6 Remain Quitters for Add'l 3 Months

- 260 adult patients highly addicted to smoking from 15 worldwide centers
- 70% previously failed 3+ quit attempts
- No systemic side effects or seizures reported



**First TMS  
Addiction  
Clearance**

# Deep TMS 360: Pilot Study




## New Tool to Improve Cognitive Performance in Patients with Dementia & MCI\*

Over 10 million people are diagnosed with mild cognitive impairment (MCI) or dementia in the U.S.

Current medications have low efficacy, primarily stabilize rather than enhance cognition, and cause debilitating side effects (e.g. GI issues, dizziness, sleep disturbances).


Corporate Presentation August 2025

### Single-Channel, Fixed Field Deep TMS



- Fixed Field Deep TMS has had some success in patients with MCI/Dementia, but moderate results may be due to atrophy and neurodegeneration in these patients
- This results in insufficient brain engagement by current TMS technology

### Multi-Channel, Rotational Field Deep TMS 360




- Deep TMS 360 targeting the prefrontal cortex is uniquely suited for older adults with neurodegenerative conditions and reduced neuroplasticity due to its greater efficiency at **activating neurons oriented in multiple directions**.
- Deep TMS is currently the only TMS technology FDA-cleared for patient over 68 years – a prime demographic for MCI and dementia

\*Not FDA Cleared

# Strong Foundation, Promising Future



Actively Pursuing Indications in Multiple Therapeutic Areas with Unmet Needs



# Practice Development Program



Support Program Proven to Increase Device Utilization, Leading to Repeat Sales



## Clinical Knowledge & Treatment Mastery

- The Deep TMS System
- Major Depressive Disorder Treatment
- Obsessive-Compulsive Disorder Treatment
- Smoking Addiction Treatment
- Patient Treatment Management



## Operational & Financial Excellence


- Site Preparation
- Patient Flow
- Practice Administration
- Preparing to Accept Insurance
- Prequalification with Insurance
- Navigating Billing



## Patient Acquisition & Retention

- Marketing Strategy
- Internal Patient Generation
- Referral Network Building
- Direct-to-Patient Marketing

Each Quarter, **>50 Practice Sites** Enrolled in the Practice Development Program Experience a **Badge Promotion**, Indicating at Least 250 Additional Treatments Completed




# New Territories



## Geographic Expansion into Japan, Europe, and Other Asian Countries

### Europe

37m Depression Patients  
Existing Partnership



Corporate Presentation August 2025

### Japan

6m Depression Patients  
Cleared for Sale  
Existing Partnership

### China

71m Depression Patients  
Existing Partnership

### India

57m Depression Patients  
Existing Partnership

### Australia

1.3m Depression Patients  
Cleared for Sale

### International Markets are Long-Term Growth Opportunities

- Japan: Secured reimbursement & signed exclusive multi-year distribution deal.
- Canada: Entered market with an exclusive multi-year agreement, including minimum annual purchase commitments.
- Israel: Expanded Deep TMS™ access to 21 new centers.
- Military & PTSD Treatment: Secured reimbursement & ongoing collaboration with Israel's Ministry of Defense.
- East Asia: Significant international deals strengthening our global footprint.

# Most Extensive and Broadest TMS Intellectual Property



## Encompassing Core Technology and Applications

### Patent Portfolio

30+  
US

50+  
OUS

Issued Patents  
or Allowed Applications

### Key Portfolio Coverage Areas

Deep TMST<sup>TM</sup> Coils  
Multi-Channel TMS  
Rotational Field Deep TMS  
Closed Loop TMS/EEG

Corporate Presentation August 2025

# Q2 2025 Financial Review



	Actual	Actual	Variance	
USD in Thousands	Q2 2025	Q2 2024	\$	%
Revenues	12,632	10,005	2,627	26%
Cost of Revenues	3,133	2,468	665	27%
Gross Profit	9,499	7,537	1,962	26%
% Margin	75.20%	75.33%		
Research and Development Expenses	2,344	1,711	633	37%
Selling and Marketing Expenses	4,940	3,796	1,144	30%
General and Administrative Expenses	1,637	1,444	193	13%
Total Operating Expenses	8,921	6,951	1,970	28%
Operating Profit	578	586		
Finance Income, Net	(1,519)	(117)	(1,402)	1198%
Taxes on Income	70	103	(33)	-32%
Net Income	2,027	600	1,435	239%
Adjusted EBITDA	1,451	1,248	203	16%
% EBITDA	11%	12%		
Basic Net Income Per Share	\$0.05	\$0.02	0.03	168%
Diluted Net Income Per Share	\$0.05	\$0.02	0.03	160%

Revenue: \$12.6M (+26% YoY)

~\$78M in cash with no debt as of Q2 2025

Positive EBITDA 8th Quarter in a row

Net Income 7th Quarter in a row

# H1 2025 Financial Review



	Actual	Actual	Variance	
USD in thousands	H1 2025	H1 2024	\$	%
Revenues	24,168	19,100	5,068	27%
Cost of Revenues	6,059	4,751	1,308	28%
<b>Gross profit</b>	<b>18,109</b>	<b>14,349</b>	<b>3,760</b>	<b>26%</b>
<b>Gross Margin</b>				
Research and Development expenses	4,676	3,337	1,339	40%
Selling and Marketing expenses	9,102	7,623	1,479	19%
General and Administrative expenses	3,177	2,710	467	17%
<b>Total Operating expenses</b>	<b>16,955</b>	<b>13,670</b>	<b>3,285</b>	<b>24%</b>
<b>Operating Profit</b>	<b>1,154</b>	<b>679</b>	<b>475</b>	<b>70%</b>
Finance Income, net	(2,207)	(307)	(1,900)	619%
Income Tax expense	227	275	(48)	-17%
<b>Net Income</b>	<b>3,134</b>	<b>711</b>	<b>2,423</b>	<b>341%</b>
<b>Adjusted EBITDA</b>	<b>2,746</b>	<b>1,963</b>	<b>783</b>	<b>40%</b>
Basic Net Income Per Share	\$ 0.08	\$ 0.02	0.06	316%
Diluted Net Income Per Share	\$ 0.07	\$ 0.02	0.05	262%

Revenue: \$24.1M (+26% YoY)

Adj. EBITDA \$2.7M

Net Income \$3.1M

# Q2 2025 Balance Sheet



USD in thousands	As of June 30,	As of March 31,	As of December 31,	Change vs. 03/25		Change vs. 12/24	
	2025	2025	2024	\$	%	\$	%
<u>ASSETS</u>							
Cash and cash equivalents	67,912	71,601	69,345	(3,689)	-5%	(1,433)	-2%
Restricted cash	251	271	271	(20)	-7%	(20)	-7%
Short-term deposits	10,087	-	-	10,087	100%	10,087	100%
Trade receivables, net	3,871	6,954	4,596	(3,083)	-44%	(725)	-16%
Inventory	4,190	4,680	4,426	(490)	-10%	(236)	-5%
Other current assets	3,179	1,150	1,032	2,029	176%	2,147	208%
<b>Total Current Assets</b>	<b>89,490</b>	<b>84,656</b>	<b>79,670</b>	<b>4,834</b>	<b>6%</b>	<b>9,820</b>	<b>12%</b>
<b>Non-Current Assets</b>	<b>22,074</b>	<b>15,542</b>	<b>14,646</b>	<b>6,532</b>	<b>42%</b>	<b>7,428</b>	<b>51%</b>
<b>Total Assets</b>	<b>111,564</b>	<b>100,198</b>	<b>94,316</b>	<b>11,366</b>	<b>11%</b>	<b>17,248</b>	<b>18%</b>
<u>LIABILITIES AND EQUITY</u>							
<b>Current Liabilities</b>	<b>25,508</b>	<b>16,846</b>	<b>15,346</b>	<b>8,662</b>	<b>51%</b>	<b>10,162</b>	<b>66%</b>
<b>Non-Current Liabilities</b>	<b>17,924</b>	<b>19,602</b>	<b>16,657</b>	<b>(1,678)</b>	<b>-9%</b>	<b>1,267</b>	<b>8%</b>
<b>Equity</b>	<b>68,132</b>	<b>63,750</b>	<b>62,313</b>	<b>4,382</b>	<b>7%</b>	<b>5,819</b>	<b>9%</b>
<b>Total Liabilities and Equity</b>	<b>111,564</b>	<b>100,198</b>	<b>94,316</b>	<b>11,366</b>	<b>11%</b>	<b>17,248</b>	<b>18%</b>

# BrainsWay Investment Highlights



## Advancing Neuroscience to Improve Health and Transform Lives

- ✓ Leading neuromodulation company with proven breakthrough technology
- ✓ Large underserved markets
- ✓ Strong momentum across our core market and successful execution of our growth strategy
- ✓ 70% of recent customer engagements are structured as multi-year lease agreements
- ✓ Major U.S. Expansion: Partnering with large mental health networks to integrate Deep TMS
- ✓ Remaining performance obligations increased by 25 % YOY to \$62 million
- ✓ Business model encouraging utilization and guaranteeing revenue generation
- ✓ Pursuing 4 new indications
- ✓ Experienced management team

# BrainsWay Leadership Team



Successful, Experienced Medical Device Professionals



**Hadar Levy**  
**Chief Executive Officer**  
25+ Years Med Device



**Ido Marom**  
**Chief Financial Officer**  
20+ Years Finance




**Dr. Gilead Moiseyev**  
**Chief Technology Officer**  
20+ Years Med Device Dev




**Dr. Richard Bermudes**  
**Chief Medical Officer**  
15+ Years TMS Leadership



**Moria Ben Soussan**  
**Vice President - R&D**  
15+ Years Med Device Dev



**Michael Cohen**  
**Vice President - US Sales**  
15+ Years Med Device Sales  
Corporate Presentation May 2025




**Yuval Gimshi**  
**Vice President - Int'l Sales**  
15+ Years Med Device Sales



**Dor Hagai**  
**Vice President - Operations**  
10+ Years Supply Chain & Ops



**Dr. Colleen Hanlon**  
**Vice President - Medical Affairs**  
15+ Years Brain Stim Research



**Ross Mitchell**  
**Vice President - Marketing**  
12+ Years Healthcare Mktg



# Thank you!

**Investor Contact:**

Ido Marom

Chief Financial Officer

[Ido.Marom@BrainsWay.com](mailto:Ido.Marom@BrainsWay.com)



## References

1. BrainsWay Data on File
2. The National Institute of Mental Health: [nimh.nih.gov](http://nimh.nih.gov)
3. Kessler RC, et al. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey Br J Psychiatry Suppl. 1996
4. Trivedi MH et al. STAR\*D Study Team (2006). Evaluation of outcomes with citalopram for depression using measurement-based care in STAR\*D: implications for clinical practice. Am J Psychiatry. 2006 Jan; 163(1):28-40.
5. Greist JH. The comparative effectiveness of treatments for obsessive-compulsive disorder. Bull Menninger Clin. 1998;62(4, suppl 1A):A65-A81
6. Marks I. Behavior therapy for obsessive-compulsive disorder: a decade of progress. Can J Psychiatry. 1997;42:1021-1027
7. Ballenger JC. Current treatments of the anxiety disorders in adults. Biol Psychiatry. 1999;46: 1579-1594
8. Lawson McLean A. Publication trends in transcranial magnetic stimulation: a 30-year panorama. Brain Stimul. 2019 May-Jun;12(3): 619-627
9. BrainsWay Data on File; Depth, measured in phantom head, is from cortical surface toward brain center for which E-field > =100V/m for calibrated stimulator output. If measuring from scalp surface, an additional 1.5 cm should be added; See also, Guadagnin, V., et. al., 2016. Deep Transcranial Magnetic Stimulation: Modeling of Different Coil Configurations. 63, 1543-1550.
10. Fiocchi, S., et. al., 2016. Modelling of the Electric Field Distribution in Deep Transcranial Magnetic Stimulation. 2016
11. Company estimates, references 3.4M adult MDD patients with insurance coverage and assumes 33 sessions per patient with an average session price of \$70; Oppenheimer Research Report, 08/24/2020
12. Tendler, A, et al. Deep TMS H1 Coil treatment for depression: Results from a large post marketing data analysis. Psychiatry Research. Vol 324, June 2023, 115179
13. Senova S, et al. Durability of antidepressant response to repetitive transcranial magnetic stimulation: Systematic review and meta-analysis. Brain Stimulation 12 (2019) 119e128
14. Gersner R, et al. What is the durability of Deep TMS for Major Depressive Disorder. Brain Stimulation 13 (2020) 1842-1862
15. Roth Y, et al. Real-world efficacy of deep TMS for obsessive-compulsive disorder: Post-marketing data collected from twenty-two clinical sites. J Psychiatr Res. 2020 Nov 4;S0022-3956(20)31065-7
16. Harmelech T et al. Long-term outcomes of a course of deep TMS for treatment-resistant OCD. Brain Stimulation 15 (2022) 226e228
17. [https://www.cdc.gov/tobacco/data\\_statistics/fact\\_sheets/cessation/smoking-cessation-fast-facts/index.html](https://www.cdc.gov/tobacco/data_statistics/fact_sheets/cessation/smoking-cessation-fast-facts/index.html). Data as of 2018 for U.S. adults.
18. EY Parthenon Analysis 2018 [https://www.smokefreeworld.org/sites/default/files/ey-p\\_smoking\\_cessation\\_landscape\\_analysis\\_key\\_findings.pdf](https://www.smokefreeworld.org/sites/default/files/ey-p_smoking_cessation_landscape_analysis_key_findings.pdf)
19. Zangen A et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021 Oct;20(3):397-404
20. <https://worldpopulationreview.com/country-rankings/depression-rates-by-country>

Corporate Presentation March 2025